NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML

被引:52
|
作者
Jayavelu, Ashok Kumar [1 ]
Moloney, Jennifer N. [2 ]
Boehmer, Frank-D. [1 ]
Cotter, Thomas G. [2 ]
机构
[1] Jena Univ Hosp, CMB, Inst Mol Cell Biol, Hans Knoll Str 2, D-07745 Jena, Germany
[2] Univ Coll Cork, Biosci Res Inst, Sch Biochem & Cell Biol, Tumour Biol Lab, Cork, Ireland
关键词
PROTEIN-TYROSINE PHOSPHATASES; ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATIONS; BCR-ABL; GENOMIC INSTABILITY; NADPH OXIDASES; DNA-DAMAGE; FLT3; ACTIVATION; MECHANISMS;
D O I
10.1016/j.exphem.2016.08.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In different types of myeloid leukemia, increased formation of reactive oxygen species (ROS) has been noted and associated with aspects of cell transformation, including the promotion of leukemic cell proliferation and migration, as well as DNA damage and accumulation of mutations. Work reviewed in this article has revealed the involvement of NADPH oxidase (NOX)-derived ROS downstream of oncogenic protein tyrosine kinases in both processes, and the related pathways have been partially identified. FMS-like tyrosine kinase 3 with internal tandem duplications (FLT3-ITD), an important oncoprotein in a subset of acute myeloid leuke-mias, causes activation of AKT and, subsequently, stabilization of p22(phox), a regulatory subunit for NOX1-4. This process is linked to ROS formation and DNA damage. Moreover, FLT3-ITD signaling through STAT5 enhances expression of NOX4, ROS formation, and inactivation of the protein tyrosine phosphatase DEP-1/PTPRJ, a negative regulator of FLT3 signaling, by reversible oxidation of its catalytic cysteine residue. Genetic inactivation of NOX4 restores DEP-1 activity and attenuates cell transformation by FLT3-ITD in vitro and in vivo. Future work is required to further explore these mechanisms and their causal involvement in leukemic cell transformation, which may result in the identification of novel candidate targets for therapy. Copyright (C) 2016 ISEH-International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:1113 / 1122
页数:10
相关论文
共 50 条
  • [31] CCL5 mediates Target-Kinase independent resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD-positive AML
    Waldeck, S.
    Rassner, M.
    Philipp, U.
    Andrieux, G.
    Keye, P.
    Waterhouse, M.
    Duyster, J.
    von Bubnoff, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 143 - 143
  • [32] LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML
    Beeharry, Neil
    Landrette, Sean
    Gayle, Sophia
    Hernandez, Marylens
    Grotzke, Jeff E.
    Young, Peter R.
    Beckett, Paul
    Zhang, Xuan
    Carter, Bing Z.
    Andreeff, Michael
    Halene, Stephanie
    Xu, Tian
    Rothberg, Jonathan
    Lichenstein, Henri
    BLOOD ADVANCES, 2019, 3 (22) : 3661 - 3673
  • [33] Inhibition of heme oxygenase 1 decreases proliferation and resensitizes TKI-resistant Flt3-ITD-positive AML cells
    Irwin, Mary E.
    Chandra, Joya
    CANCER RESEARCH, 2015, 75
  • [34] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
    Jeon, Jae Yoon
    Zhao, Qiuhong
    Buelow, Daelynn R.
    Phelps, Mitch
    Walker, Alison R.
    Mims, Alice S.
    Vasu, Sumithira
    Behbehani, Gregory
    Blachly, James
    Blum, William
    Klisovic, Rebecca B.
    Byrd, John C.
    Garzon, Ramiro
    Baker, Sharyn D.
    Bhatnagar, Bhavana
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 340 - 349
  • [35] Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
    Jae Yoon Jeon
    Qiuhong Zhao
    Daelynn R. Buelow
    Mitch Phelps
    Alison R. Walker
    Alice S. Mims
    Sumithira Vasu
    Gregory Behbehani
    James Blachly
    William Blum
    Rebecca B. Klisovic
    John C. Byrd
    Ramiro Garzon
    Sharyn D. Baker
    Bhavana Bhatnagar
    Investigational New Drugs, 2020, 38 : 340 - 349
  • [36] Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy
    Kannan, Sankaranarayan
    Irwin, Mary E.
    Herbrich, Shelley M.
    Cheng, Tiewei
    Patterson, LaNisha L.
    Aitken, Marisa J. L.
    Bhalla, Kapil
    You, M. James
    Konopleva, Marina
    Zweidler-McKay, Patrick A.
    Chandra, Joya
    ANTIOXIDANTS, 2022, 11 (04)
  • [37] Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
    Meshinchi, Sohell
    Arceci, Robert J.
    Sanders, Jean E.
    Smith, Franklin O.
    Woods, William B.
    Radich, Jerald R.
    Alonzo, Todd A.
    BLOOD, 2006, 108 (01) : 400 - 400
  • [38] REACTIVE OXYGEN SPECIES (ROS) MODULATES SENSITIVITY TO FLT3-TYROSINE KINASE INHIBITORS IN MURINE AND HUMAN FLT3-ITD POSITIVE AML CELL LINES
    Mueller, C.
    Simeoni, L.
    Heidel, F.
    Schraven, B.
    Fischer, T.
    HAEMATOLOGICA, 2016, 101 : 362 - 363
  • [39] TARGETING THE DBC1-SIRT1-P53 AXIS IS A PROMISING THERAPEUTIC STRATEGY IN FLT3-ITD-POSITIVE AML
    Sasca, D.
    Haehnel, P.
    Al-Khawaja, K.
    Bullinger, L.
    Theobald, M.
    Kindler, T.
    HAEMATOLOGICA, 2013, 98 : 401 - 401
  • [40] Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia
    Kakiuchi, Seiji
    Yakushijin, Kimikazu
    Sakai, Rina
    Kawaguchi, Koji
    Higashime, Ako
    Kurata, Keiji
    Ichikawa, Hiroya
    Nagao, Shigeki
    Rikitake, Junpei
    Kiyota, Naomi
    Matsuoka, Hiroshi
    Minami, Hironobu
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2010 - 2015